Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €69.02 EUR
Change Today +0.03 / 0.04%
Volume 212.7K
As of 11:35 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

ucb sa (UCB) Snapshot

Open
€69.42
Previous Close
€68.99
Day High
€69.86
Day Low
€68.45
52 Week High
08/29/14 - €75.62
52 Week Low
05/21/14 - €55.34
Market Cap
13.4B
Average Volume 10 Days
286.1K
EPS TTM
€0.60
Shares Outstanding
194.5M
EX-Date
05/4/15
P/E TM
115.0x
Dividend
€1.06
Dividend Yield
1.51%
Current Stock Chart for UCB SA (UCB)

Related News

No related news articles were found.

ucb sa (UCB) Related Businessweek News

No Related Businessweek News Found

ucb sa (UCB) Details

UCB S.A., a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system in Belgium and internationally. The company’s core products include Cimzia for Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis/ankylosing spondylitis; Vimpat for the treatment of epilepsy partial-onset seizures (POS); and Neupro for Parkinson’s disease and restless legs syndrome. It also offers Keppra for epilepsy POS, epilepsy primary generalized tonic-clonic seizures (PGTCS), and epilepsy myoclonic seizures; Zyrtec and Xyzal for allergy; Metadate for attention deficit and hyperactivity disorders; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for narcolepsy with cataplexy in adult patients. In addition, the company provides Tussionex for relief of cough and upper respiratory symptoms associated with allergy or a cold; and Lortab for the relief from pain. The company’s product pipeline includes brivaracetam as an adjunctive therapy for epilepsy POS; Vimpat for various types of epilepsy; UCB4942 for drug resistant epilepsy; epratuzumab for systemic lupus erythematosus; romosozumab for osteoporosis; UCB4940 for psoriatic arthritis; UCB5857 for immune-inflammatory diseases; UCB7665 for immunological diseases; and dapirolizumab pegol for systemic lupus erythematosus. The company has strategic alliances with the Weill Cornell Medical College (U.S.), Sanofi, and Dermira Inc., as well as collaboration agreement with Neuropore Therapies Inc. UCB S.A. was founded in 1928 and is headquartered in Brussels, Belgium.

8,535 Employees
Last Reported Date: 02/28/15
Founded in 1928

ucb sa (UCB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

ucb sa (UCB) Key Developments

UCB S.A. Presents at 10th Annual Neurotech Investing & Partnering Conference, Apr-07-2015 02:00 PM

UCB S.A. Presents at 10th Annual Neurotech Investing & Partnering Conference, Apr-07-2015 02:00 PM. Venue: Hotel Nikko, 222 Mason Street, San Francisco, California, United States. Speakers: Doreen Grech, Director External Partnerships, CNS Practice.

UCB Announces Earnings Results for the Financial Year 2014; Provides Earnings Guidance for the Year 2015

UCB announced earnings results for the financial year 2014. For the year, the company reported that revenues increased by 7% year on year (y/y) on a reported basis to EUR 3.3 billion. Net sales were up 5% y/y to EUR 2.9 billion. In particular, the company's core product portfolio - Cimzia (certolizumab), Vimpat (lacosamide), and Neupro (rotigotine) accounted for 50% of overall company sales and boosted company performance by bringing combined sales growth of 24% y/y, edging up to EUR 1.5 billion. The company provided earnings guidance for the year 2015. Looking at the financial outlook published by the company, the firm is confident that the core portfolio of products will continue to deliver sustained growth in 2015. In particular, the company forecasted achieving revenues of approximately EUR 3.55 billion to EUR 3.65 billion. Furthermore, recurring EBITDA is expected to attain EUR 710 million to -740 million.

UCB S.A., 2014 Earnings Call, Feb 27, 2015

UCB S.A., 2014 Earnings Call, Feb 27, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UCB:BB €69.02 EUR +0.03

UCB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $93.27 USD -0.81
Grifols SA €40.43 EUR +0.24
Hospira Inc $87.61 USD -0.05
Lonza Group AG SFr.129.30 CHF +0.20
Sigma-Aldrich Corp $139.00 USD +0.03
View Industry Companies
 

Industry Analysis

UCB

Industry Average

Valuation UCB Industry Range
Price/Earnings 100.0x
Price/Sales 3.5x
Price/Book 2.4x
Price/Cash Flow 57.7x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UCB SA, please visit www.ucb.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.